Qritive, a healthcare AI startup headquartered in Singapore with presence in the US, Singapore, and India, announced raising $7.5 million in a funding round led by MassMutual Ventures, supported by SEEDS Capital, the investment arm of Enterprise Singapore, and Exfinity Venture Partners.
Qritive said it will use this new capital to drive geographical expansion, expand product portfolio and support regulatory clearances.
Founded in 2017 by Dr. Aneesh Sathe and Dr. Kaveh Taghipour, Qritive today has presence in Singapore, USA, and India. Using artificial intelligence, Qritive solutions provide fast and accurate interpretations of pathology whole slide images scans within seconds, reducing time to treatment, increasing accuracy for cancer care.
In an environment where 70% of the pathologists are concentrated in just 10 countries, leaving 47% of the world population without basic access to diagnostics, the transition to digital pathology is becoming increasingly critical in the agenda of healthcare systems.
In this context, Qritive brings clinical-grade AI-powered solutions to enable histopathology diagnosis of cancer at scale. These clinical-decision support tools help improve efficiency and quality in diagnosis, which will ultimately result in better patient outcome.
As Aneesh Sathe, CEO of Qritive, put it: “Complexity of diagnostics has increased considerably and having tools that increase accuracy and throughput really fast has become instrumental for clinicians worldwide.”
Qritive’s solutions are CE certified and also approved by Singapore Health Sciences Authority (HSA) for clinical use. Qritive’s technology helps accelerate cancer diagnosis across multiple cancer types including colon, prostate, lymph node, breast and includes a robust set of tools for immunohistochemistry.
“Qritive’s platform digitizes and streamlines the pathology workflow from end-to-end, supporting clinicians with a wide range of tools – including image analysis, case management, and reporting modules,” said Ryan Collins, Managing Director at MassMutual Ventures.
“With an international network of pathologists, Qritive is uniquely positioned to accelerate the adoption of digital pathology across the globe. We look forward to supporting Qritive’s growth and the meaningful work that it is doing to improve patient outcomes,” he added.